In two phase 2 trials in which patients with refractory NPC were treated with the anti-PD1 antibodies pembrolizumab or nivolumab as monotherapy, overall response rates of 26% and 20.5%, respectively, were observed [15, 16]. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.